I'm grateful to have found this network. I've spent many hours over reading your posts and replies, and learning from you all. Thank you.
I'm 59 years old. Both my father and brother were diagnosed with PCa in their late 50s. I did a genome test for my family some years ago and learned I carry the ATM gene.
I've been getting PSA tests since turning 40. Since 2017, my scores have been gradually increasing from 2.3 ng/ml to 3.3 to 3.6 ng/ml in 2023. A 4K score of 5.1 was logged in late June with a total PSA of 3.41, free PSA of 0.87 and 26% free PSA.
In late July, following the advice of my Urologist, I got an MRI of my prostrate w/wo IV contrast. Two PI-RADs 3 lesions were identified. Here are the specifics:
Lesion 1.
A 2.3 x 2.1 x 0.8 cm area of ill-defined T2 hypointensity posteromedial and posterolateral right peripheral zone mid gland and apex.
T2 appearance: Diffuse mild hypointensity.
Diffusion-Weighted Imaging: Focal hypointense on ADC and/or focal hyperintense on DWI.
Enhancement: Negative.
Prostate margin: No involvement.
Diffusion abnormality meets PI-RADS 3.
Region of interest created for biopsy and/or follow-up.
Lesion 2.
A 2.1 x 1.8 x 0.6 cm area of ill-defined T2 hypointensity posteromedial and posterolateral left peripheral zone mid gland and apex.
T2 appearance: Diffuse mild hypointensity.
Diffusion-Weighted Imaging: Focal hypointense on ADC and/or focal hyperintense on DWI.
Enhancement: Negative.
Prostate margin: No involvement.
Diffusion abnormality meets PI-RADS 3.
Region of interest created for biopsy and/or follow-up.
TRANSITIONAL ZONE: No suspicious focal finding in the transitional zone. Mild stromal and glandular BPH.
No seminal vesicle invasion.
No pelvic lymphadenopathy.
No lesions in the visualized bones.
PROSTATE GLAND VOLUME: 45 cc
These results triggered a prostate biopsy. I got that done last week. I discuss the results with my Urologist tomorrow. Lots of details here but here is a synopsis: 14 cores, several targeted specifically at the lesions. All that threw up red flags -- there were 8 of them -- were Grade Group 1 (Gleason grade 3+3, score 6). Percent tissue involvement included two at less than 5%, two at 10%, one in the 20 percentile, 1 in at 30% and two that scored 40%. Multifocal perineural invasion is present.
I've learned that I do not need to decide right away. I've also learned that it may be advisable to request a second opinion on the biopsy results (I've been pondering the advice of sending it to John Hopkins). On biopsy day, I brought up Decipher and my Urologist seemed amenable to it, pending results.
I live near the Mayo Clinic in Rochester, MN, although I am not currently a patient, so ruminating on that.
I wonder how accurate my biopsy results are, wondering if my 3+3s are really 3+4s, or something other in either direction. I've read posts about post surgical upgrades.
I'm anxious about all that ATM stuff, and how those of us with this rare gene type are more susceptible to aggressive PCa. I should note here that my living brother had Gleasons in the 9s and has had aggressive treatment -- the battery of prostectomy, radiation, ADT, etc. My deceased father did not die of PCa (and was a regular Lupron receiver).
I'm inclined to want to act while a window exists to take action (someone said, while the cows are still in the barn...I relate to that). I'm also in tune with the studies about over treatment of PCa, and how the Grade Group 1 patients are especially called out. I can relate to how many just want to get past the diagnosis.
I want to hear first what my Urologist has to say, so I plan to very actively listen. I've been satisfied with his care to date. I'm inclined to do one year (or less if the case may be) of AS, thinking that'd be keeping the PSA checks every six months, getting the Decipher test, requesting a second read of my biopsy results, getting another scan and then set of biopsies at the 9 month mark.
It is open enrollment, so I've been contemplating a move that makes Mayo in Rochester more accessible but on the fence on this.
Any thoughts you might have I very much welcome. Thank you for your consideration.